IMRX

Immuneering Corp. Class A · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website immuneering.com
Employees(FY) 67
ISIN US45254E1073

Performance

+1.52%

-1.96%

-17.36%

+35.14%

-72.79%

YTD

-70.15%

Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Advanced Technical Analysis

Technical Analysis of IMRX 2024-12-20

The stock exhibits a bullish sentiment overall, with a strong Moving Average Score of 76 indicating positive momentum, while the Oscillators Score of 56 suggests a neutral stance. The combined Technical Score of 66 reinforces the bullish outlook, signaling potential upward movement in the stock's price.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of IMRX

Stock Rank

Recent News & Updates

2024-12-18 19:00
Immuneering Launches Pancreatic Cancer Advisory Board(Globenewswire)
2024-12-16 19:00
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025(Globenewswire)
2024-12-13 01:10
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?(Yahoo Finance)
2024-12-11 19:00
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma(Globenewswire)
2024-11-26 19:00
Immuneering to Present at the Piper Sandler 36 Annual Healthcare Conference(Globenewswire)
2024-11-13 03:05
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates(Globenewswire)
2024-10-14 20:00
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer(Globenewswire)
2024-09-12 20:14
Why Is Nanocap Immuneering Stock Trading Higher On Friday?(Yahoo Finance)
2024-09-12 04:05
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients(Globenewswire)
2024-08-28 20:00
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference(Globenewswire)
2024-08-06 04:05
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates(Yahoo Finance)
2024-07-31 04:05
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer(Globenewswire)
2024-05-29 04:05
Immuneering to Present at the Jefferies Global Healthcare Conference(Globenewswire)
2024-05-17 00:50
Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment(Prnewswire)
2024-05-07 10:55
IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024(Investorplace)
2024-05-07 04:05
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates(Globenewswire)
2024-05-06 04:30
Immuneering Recognizes Melanoma Awareness Month(Globenewswire)
2024-04-09 00:00
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models(Globenewswire)
2024-04-03 04:05
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference(Globenewswire)
2024-03-26 20:00
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations(Globenewswire)
2024-03-17 23:02
Immuneering (IMRX) Plummets 71% in One Week: Here's Why(Zacks)
2024-03-13 19:00
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors(Globenewswire)
2024-03-11 20:00
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors(Globenewswire)
2024-03-10 20:00
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors(Globenewswire)
2024-03-05 19:00
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning(Newsfilecorp)
2024-03-05 04:00
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024(Globenewswire)
2024-03-03 19:00
Immuneering to Participate in the Cowen 44th Annual Health Care Conference(Globenewswire)
2024-03-03 06:01
Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results(Yahoo Finance)
2024-02-29 19:00
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates(Globenewswire)
2024-02-19 19:00
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer(Globenewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.